Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Gets $2.9M Task Order from EPA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today said that it has received a $2.9 million task order from the Environmental Protection Agency for the agency's ToxCast screening program.

This is the second order for Caliper from EPA under Phase II of the ToxCast program. In November, the EPA awarded the firm a $1.8 million order to screen as many as 700 compounds against Caliper's ToxCast assay panel.

The goal of the ToxCast program is to identify in vitro assays that can predict the toxicity of chemical compounds in humans and animals by comparing the results of testing conducted by Caliper and other contractors with toxicity data in the EPA's in vivo toxicity database, ToxRefDB. The predictive tests would then be used to supplement or replace existing animal-based tests, thereby reducing cost and improving the speed of regulatory approval of new environmental chemicals.

"We have seen increased interest from the pharmaceutical, chemical, and cosmetic industries in [Caliper Discovery Alliances and Services'] commercial services based on in vitro toxicology assays represented in the ToxCast panel," David Manyak, executive VP of drug discovery services for Caliper, said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.